Anastrozole for Postmenopausal Women with Estrogen Receptor-Positive Breast Cancer
Indications
Anastrozole is FDA-approved for three specific settings in postmenopausal women with hormone receptor-positive breast cancer: adjuvant treatment of early breast cancer, first-line treatment of locally advanced or metastatic disease, and second-line treatment after tamoxifen failure 1.
The drug works by selectively inhibiting the aromatase enzyme, which converts adrenal androgens to estrogens in postmenopausal women, reducing serum estradiol by approximately 70% within 24 hours and 80% after 14 days 1.
Dosing Regimen
The standard dose is 1 mg orally once daily 1. This dose achieves near-maximal suppression of serum estrogens and reduces estradiol to the lower limit of detection (3.7 pmol/L) 1.
Duration of Treatment
For adjuvant therapy:
- Standard duration is 5 years 2
- Extended therapy for an additional 5 years (total 10 years) significantly improves disease-free survival 3. In the AERAS trial, continuing anastrozole for 10 years versus stopping at 5 years resulted in 5-year DFS rates of 91% versus 86% (HR 0.61, P<0.001), with particular reduction in local recurrence and second primary cancers 3
- Extended therapy can be given after 5 years of anastrozole alone OR after 2-3 years of tamoxifen followed by 2-3 years of anastrozole 2, 3
Food reduces the rate but not the extent of absorption—anastrozole can be taken with or without food 1.
Contraindications and Precautions
Anastrozole is contraindicated in premenopausal women 1. Because aromatization of adrenal androgens is not a significant source of estradiol in premenopausal women, anastrozole would not be expected to lower estradiol levels in this population and should not be used 1.
Critical pitfall: Patients with ER-negative disease and those who did not respond to previous tamoxifen therapy rarely respond to anastrozole 1. Do not use in these populations.
Required Monitoring
Bone Health Monitoring
The most important adverse effect requiring monitoring is bone loss and increased fracture risk 2, 3. While the AERAS trial showed bone-related adverse events were more frequent with extended therapy, grade ≥3 events occurred in <1% of patients 3.
Monitor:
- Baseline bone density assessment before initiating therapy
- Periodic bone density scans during treatment
- Consider bisphosphonates or denosumab for patients with osteoporosis or high fracture risk
Other Monitoring
- No glucocorticoid or mineralocorticoid replacement therapy is necessary—anastrozole does not affect cortisol or aldosterone secretion 1
- No routine thyroid monitoring required (no increase in TSH observed) 1
- Liver function should be monitored as hepatic metabolism accounts for approximately 85% of elimination 1
Common Adverse Effects
Anastrozole is generally well tolerated with a low withdrawal rate (2%) due to drug-related adverse events 4.
Most Common Adverse Effects:
- Gastrointestinal disturbances (29-33%): generally mild, moderate, and transient 5
- Vasomotor symptoms/hot flushes (≤12%) 5, 6
- Musculoskeletal symptoms (≤16% asthenia, ≤15% pain, ≤12% bone pain, ≤11% back pain) 5, 7
- Headache (≤18%) 5
Advantages Over Tamoxifen:
Anastrozole has significantly fewer thromboembolic events and less vaginal bleeding compared to tamoxifen 8, 4. In first-line therapy trials, thromboembolic events occurred in 4.1% with anastrozole versus 8.2% with tamoxifen, and vaginal bleeding in 1.2% versus 3.8% 8.
Unlike tamoxifen, anastrozole does not increase risk of endometrial cancer 6.
Key Difference from Megestrol Acetate:
Anastrozole causes significantly less weight gain than megestrol acetate 4, 5, making it preferable for second-line therapy.
Clinical Positioning
For metastatic disease, nonsteroidal aromatase inhibitors (anastrozole or letrozole) are preferred first-line agents for postmenopausal women without prior adjuvant endocrine therapy or with late relapse (>12 months) after adjuvant tamoxifen 9.
For early relapse (≤12 months) after adjuvant AI therapy, switch to fulvestrant ± palbociclib rather than continuing the same AI 9.